Dr. Chima-Melton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1145 W Redondo Beach Blvd
Gardena, CA 90247
Summary
- Chidinma Chima-Melton, MD, is a Pulmonology specialist based in Porter Ranch, CA. She also has expertise in Critical Care Medicine and Pleural Disease. Dr. Chima-Melton completed her education with a fellowship in Pulmonary Disease and Critical Care Medicine from Cedars-Sinai Medical Center after completing her residency in Internal Medicine at Yale-New Haven Medical Center. She has made significant contributions to medical literature, including publications on treatments for COVID-19 and hypertension management. She is notably recognized for her work on Remdesivir's impact on COVID-19.
Education & Training
- Cedars-Sinai Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2013 - 2016
- Yale-New Haven Medical CenterResidency, Internal Medicine, 2010 - 2013
- Stony Brook University Health Sciences Center School of MedicineClass of 2010
Certifications & Licensure
- CA State Medical License 2013 - 2026
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- 1 citationsRemdesivir Effectiveness in Reducing the Risk of 30-Day Readmission in Vulnerable Patients Hospitalized for COVID-19: A Retrospective US Cohort Study Using Propensity ...Essy Mozaffari, Aastha Chandak, Robert L Gottlieb, Andre C Kalil, Heng Jiang
Clinical Infectious Diseases. 2024-12-13 - 1 citationsRemdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era.Essy Mozaffari, Aastha Chandak, Robert L Gottlieb, Chidinma Chima-Melton, Mark Berry
Clinical Infectious Diseases. 2024-12-13 - 1 citationsLower mortality risk associated with remdesivir + dexamethasone versus dexamethasone alone for the treatment of patients hospitalized for COVID-19.Essy Mozaffari, Aastha Chandak, Robert L Gottlieb, Chidinma Chima-Melton, Mark Berry
Clinical Infectious Diseases. 2024-09-20
Press Mentions
- Remdesivir Cuts Risk of Mortality, Hospital Readmission in Hospitalized COVID-19 PatientsFebruary 22nd, 2023
- Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across All Variant Time Periods in a Real World Study of More Than 500,000 Hospitalized PatientsFebruary 21st, 2023
- Hyperbaric Oxygen Resolves COVID-19 Breathing Problems Much Faster Than Standard TherapyJanuary 11th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: